Anserine, a Histidine-Containing Dipeptide, Suppresses Pressure Overload-Induced Systolic Dysfunction by Inhibiting Histone Acetyltransferase Activity of p300 in Mice

• Published in: International journal of molecular sciences 2024-02, Vol.25 (4), p.2344
• Main Authors: Sunagawa, Yoichi, Tsukabe, Ryosuke, Irokawa, Yudai, Funamoto, Masafumi, Suzuki, Yuto, Yamada, Miho, Shimizu, Satoshi, Katanasaka, Yasufumi, Hamabe-Horiike, Toshihide, Kawase, Yuto, Naruta, Ryuya, Shimizu, Kana, Mori, Kiyoshi, Hosomi, Ryota, Komiyama, Maki, Hasegawa, Koji, Morimoto, Tatsuya
• Format: Article
• Language: English
• Subjects: Acetylation; Animals; anserine; Anserine - pharmacology; Cardiac function; Cardiomegaly - genetics; cardiomyocyte hypertrophy; Cardiomyocytes; Cardiomyopathies - metabolism; Cardiovascular agents; Enzyme Inhibitors - pharmacology; Genes; Heart failure; Heart Failure - metabolism; Histidine; histone acetyltransferase activity; Histones; Histones - metabolism; Humans; Hypertension; Kidneys; Male; Mice; Mice, Inbred C57BL; Myocytes, Cardiac - drug effects; Myocytes, Cardiac - metabolism; Oral administration; p300; p300-CBP Transcription Factors - antagonists & inhibitors; Phenylephrine - pharmacology; pressure overload
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms25042344

Anserine, an imidazole dipeptide, is present in the muscles of birds and fish and has various bioactivities, such as anti-inflammatory and anti-fatigue effects. However, the effect of anserine on the development of heart failure remains unknown. We cultured primary cardiomyocytes with 0.03 mM to 10 mM anserine and stimulated them with phenylephrine for 48 h. Anserine significantly suppressed the phenylephrine-induced increases in cardiomyocyte hypertrophy, ANF and BNP mRNA levels, and histone H3K9 acetylation. An in vitro histone acetyltransferase (HAT) assay showed that anserine directly suppressed p300-HAT activity with an IC of 1.87 mM. Subsequently, 8-week-old male C57BL/6J mice were subjected to transverse aortic constriction (TAC) and were randomly assigned to receive daily oral treatment with anserine-containing material, Marine Active (60 or 200 mg/kg anserine) or vehicle for 8 weeks. Echocardiography revealed that anserine 200 mg/kg significantly prevented the TAC-induced increase in left ventricular posterior wall thickness and the decrease in left ventricular fractional shortening. Moreover, anserine significantly suppressed the TAC-induced acetylation of histone H3K9. These results indicate that anserine suppresses TAC-induced systolic dysfunction, at least in part, by inhibiting p300-HAT activity. Anserine may be used as a pharmacological agent for human heart failure therapy.